Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
ACT-AD ERP P300 Latency post hoc analysis: mITT population, Wilcoxon analysis ACT-AD ERP P300 Latency post hoc analysis: mITT population,...